Logo image of PHGE

BIOMX INC (PHGE) Stock Fundamental Analysis

USA - NYSEARCA:PHGE - US09090D3017 - Common Stock

0.607 USD
-0.02 (-2.68%)
Last: 10/16/2025, 10:52:35 AM
Fundamental Rating

2

Taking everything into account, PHGE scores 2 out of 10 in our fundamental rating. PHGE was compared to 536 industry peers in the Biotechnology industry. The financial health of PHGE is average, but there are quite some concerns on its profitability. PHGE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PHGE had negative earnings in the past year.
In the past year PHGE has reported a negative cash flow from operations.
In the past 5 years PHGE always reported negative net income.
In the past 5 years PHGE always reported negative operating cash flow.
PHGE Yearly Net Income VS EBIT VS OCF VS FCFPHGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -48.80%, PHGE is in line with its industry, outperforming 51.49% of the companies in the same industry.
PHGE has a Return On Equity of -96.91%. This is comparable to the rest of the industry: PHGE outperforms 46.64% of its industry peers.
Industry RankSector Rank
ROA -48.8%
ROE -96.91%
ROIC N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
PHGE Yearly ROA, ROE, ROICPHGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

PHGE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHGE Yearly Profit, Operating, Gross MarginsPHGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, PHGE has less shares outstanding
Compared to 5 years ago, PHGE has more shares outstanding
There is no outstanding debt for PHGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PHGE Yearly Shares OutstandingPHGE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHGE Yearly Total Debt VS Total AssetsPHGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -9.35, we must say that PHGE is in the distress zone and has some risk of bankruptcy.
PHGE's Altman-Z score of -9.35 is on the low side compared to the rest of the industry. PHGE is outperformed by 71.27% of its industry peers.
PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.35
ROIC/WACCN/A
WACCN/A
PHGE Yearly LT Debt VS Equity VS FCFPHGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

PHGE has a Current Ratio of 2.66. This indicates that PHGE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHGE (2.66) is worse than 67.91% of its industry peers.
A Quick Ratio of 2.66 indicates that PHGE has no problem at all paying its short term obligations.
PHGE has a Quick ratio of 2.66. This is in the lower half of the industry: PHGE underperforms 66.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
PHGE Yearly Current Assets VS Current LiabilitesPHGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PHGE have decreased strongly by -60.04% in the last year.
EPS 1Y (TTM)-60.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PHGE will show a small growth in Earnings Per Share. The EPS will grow by 6.74% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.25%
EPS Next 2Y23.86%
EPS Next 3Y14.15%
EPS Next 5Y6.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHGE Yearly Revenue VS EstimatesPHGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 100M 200M 300M
PHGE Yearly EPS VS EstimatesPHGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHGE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHGE Price Earnings VS Forward Price EarningsPHGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHGE Per share dataPHGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PHGE's earnings are expected to grow with 14.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.86%
EPS Next 3Y14.15%

More info and screens

0

5. Dividend

5.1 Amount

PHGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMX INC

NYSEARCA:PHGE (10/16/2025, 10:52:35 AM)

0.607

-0.02 (-2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners40.03%
Inst Owner Change0%
Ins Owners1.46%
Ins Owner Change9.12%
Market Cap16.12M
Analysts82.5
Price Target15.81 (2504.61%)
Short Float %1.82%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.96%
Min EPS beat(2)-0.76%
Max EPS beat(2)42.68%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.95%
EPS NY rev (1m)23.68%
EPS NY rev (3m)5.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 2.27
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0
BVpS0.72
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.8%
ROE -96.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -9.35
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.92%
Cap/Depr(5y)40.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.86%
EPS Next Y43.25%
EPS Next 2Y23.86%
EPS Next 3Y14.15%
EPS Next 5Y6.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.68%
EBIT Next 3Y-11.29%
EBIT Next 5Y-5.98%
FCF growth 1Y-34.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.22%
OCF growth 3YN/A
OCF growth 5YN/A